Atara gets FDA approval to start two phase 3 studies to assess tabelecleucel in patients with EBV+PTLD
The Company plans to initiate these studies imminently. Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic